Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

• Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
• https://x.com/RichardPAConway/status/1858557782405833156/photo/1

Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it. @rheumnow abst#2160 #ACR24

In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr

• https://x.com/bella_mehta/status/1858558034366304734/photo/1

Reproductive Issues in axSpA: Fertility and Pregnancy axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu

Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq

• Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data f…
• https://x.com/RichardPAConway/status/1858553252964692082/photo/1

A#2291 ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens Symptomatology is complex in SjD and beyond traditional disease activity markers @RheumNow #ACR24 https://t.co/AhstAFjOVS

• https://x.com/ericdeinmd/status/1858553904314667181/photo/1

Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex. Race/ethnicity + income modify the effects - Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities @RheumNow #ACR24

Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage - ↑ ADI didn’t correlate with ER visits or hospitalizations, but ↓ Childhood Opportunity Index (COI) did: ER visits: aOR 2.85 (95%CI 1.12-7.26) Hospitalizations: aOR 4.15 (95%CI 1.25-13.81) @RheumNow #ACR24 https://t.co/dVZi8oqBnI

• https://x.com/AkhilSoodMD/status/1858546709539824057/photo/1

Harkins @DrTrishHarkins et al. Impact of AC joint OA in PMR. 67% of PMR have AC joint OA. Those who do have worse pain and fatigue scores. @RheumNow #ACR24 Abstr#1974 https://t.co/vAqVuQ5Jzm https://t.co/zx5MMtWdBE

• The Impact of Concomitant Shoulder Osteoarthritis in Polymyalgia Rheumatica - A…
• https://x.com/RichardPAConway/status/1858546961185693877/photo/1

US biosimilar exp Interchangeable biosimilar - can substitute for reference product wo consulting MD Primary endpt: pharmacokinetic data 61 approved biosimilars @RheumKay: “pts should share in financial benefits” Currently 5-87% discount #PBMReform @ACRheumDC @RheumNow #ACR24 https://t.co/RqwbZalZko

• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1

In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%) This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts. @rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I

• https://x.com/RHEUMarampa/status/1858547480293450040/photo/1

Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl

• https://x.com/synovialjoints/status/1858547702696419400/photo/1

A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

• https://x.com/i/web/status/1858548221381075437
• https://x.com/synovialjoints/status/1858548221381075437/photo/1

#2286🔬Certolizumab Pegol (CZP) in High RF RA 📊Pooled analysis;N=1180 💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%) 💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%) #ACR24 @RheumNow https://t.co/koel7SDsUb

• https://x.com/CaoilfhionnMD/status/1858548471554605138/photo/1